Kymera Therapeutics (KYMR) Other Operating Expenses (2024 - 2025)

Kymera Therapeutics (KYMR) has reported Other Operating Expenses for 4 consecutive years, with $73.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses rose 35.87% year-over-year to $73.2 million; the TTM figure through Mar 2026 stood at $30.2 million (down 79.3% YoY), while the FY2025 annual figure was $3.9 million, down 97.59% from the prior year.
• Other Operating Expenses improved to $73.2 million in Q1 2026 per KYMR's latest filing, from -$161.1 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $94.4 million in Q4 2023 and bottomed at -$161.1 million in Q4 2025.
• Historically, Other Operating Expenses has averaged $30.6 million across 4 years, with a median of $53.9 million in 2025.
• On a YoY basis, Other Operating Expenses climbed as much as 993.95% in 2025 and fell as far as 456.32% in 2025.
• Kymera Therapeutics' Other Operating Expenses stood at $94.4 million in 2023, then tumbled by 52.1% to $45.2 million in 2024, then sank by 456.32% to -$161.1 million in 2025, then soared by 145.44% to $73.2 million in 2026.
• Business Quant data shows KYMR's Other Operating Expenses at $73.2 million in Q1 2026, -$161.1 million in Q4 2025, and $56.0 million in Q3 2025.